|1.||Alfaro, Vicente: 2 articles (08/2015 - 05/2012)|
|2.||Coronado, Cinthya: 2 articles (08/2015 - 05/2012)|
|3.||Perez-Soler, Roman: 2 articles (08/2011 - 07/2009)|
|4.||Zou, Yiyu: 2 articles (08/2011 - 07/2009)|
|5.||Jimeno, José: 2 articles (08/2011 - 07/2009)|
|6.||Ling, Yi-He: 2 articles (08/2011 - 07/2009)|
|7.||Aracil, Miguel: 2 articles (08/2011 - 07/2009)|
|8.||Undevia, Samir D: 1 article (08/2015)|
|9.||Ratain, Mark J: 1 article (08/2015)|
|10.||Schilsky, Richard L: 1 article (08/2015)|
11/01/2012 - "A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors."
01/01/2015 - "We have previously defined that elisidepsin (Irvalec®, PM02734) inserts and self-organizes in the plasma membrane of tumor cells, inducing a rapid loss of membrane integrity, cell permeabilization and necrotic death. "
08/01/2012 - "PM02734 is a chemically synthesized depsipeptide derived from the marine kahalalides family with a broad spectrum of activity against solid tumors in vitro and in vivo, but presenting low bioavailability. "
08/15/2011 - "In vivo, PM02734 significantly inhibited subcutaneous A549 tumor growth in nude mice (P < 0.05) in association with induction of autophagy. "
12/01/2008 - "These findings may have important implications in the development of PM02734 because tumor cells with high FA2H expression are expected to be particularly sensitive to this drug."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2009 - "The cytotoxicity of PM02734 has been determined in a panel of human NSCLC (non-small cell lung cancer) cell lines. "
07/01/2009 - "Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models."
|1.||erlotinib (CP 358,774)
|2.||Heterologous Transplantation (Xenotransplantation)